Singapore, Feb. 12 -- Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has announced an exclusive global license agreement with China-based Suzhou Ribo Life Science Co. and its subsidiaryRibocure Pharmaceuticals AB for six preclinical small interfering RNA (siRNA) programs. siRNAs offer a precision approach to gene silencing in MASH by selectively reducing the production of disease-driving proteins.

Small interfering RNAs (siRNAs) offer a precision approach to gene silencing in MASH by selectively reducing the production of disease-driving proteins. When linked to a GalNAc ligand, siRNA molecules are delivered directl...